Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04111692 · ClinicalTrials.gov registry record
A Prospective Observational Study of Foam Sclerotherapy .
A clinical trial of Autosomal Dominant Polycystic Kidney and Renal Cyst, sponsored by Mayo Clinic.
- Recruiting
- Registry status
- 100
- Enrollment target
- 1
- Study location
NCT04111692: Recruiting study of Autosomal Dominant Polycystic Kidney and Renal Cyst, sponsored by Mayo Clinic.
NCT04111692 is a study of Autosomal Dominant Polycystic Kidney and Renal Cyst that is actively recruiting participants, run by Mayo Clinic. The registered enrollment target is 100 participants, above the 88-participant average among 6 other Autosomal Dominant Polycystic Kidney trials with a reported enrollment target (14% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04111692, a study of Autosomal Dominant Polycystic Kidney and Renal Cyst, is actively recruiting participants, sponsored by Mayo Clinic.
- RECRUITING
- Registry status
- 100 participants
- Enrollment target
- 1
- Study location
Study Summary
An observational prospective study to determine the impact of foam sclerotherapy of large, dominant kidney/liver cysts on quality of life outcomes and kidney/liver cyst volumes at up to 12 months of follow-up in patients with autosomal dominant polycystic kidney disease (ADPKD) and autosomal dominant polycystic liver disease (ADPLD).
Primary Outcome
Measured using self assessed brief pain inventory (short form) questionnaire, using a scale of 0 is no pain and 10 is pain as bad as you can imagine
Conditions Studied
Study Locations (1)
Minnesota
- Mayo Clinic - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2017-11-06 |
| Est. Completion | 2027-11 |
What NCT04111692 shows while recruiting
NCT04111692 is an observational study that tracks outcomes without assigning an intervention. The registered 100 participants enrollment target is mid-sized for trials with a published cap, above the 88-participant average among 6 other Autosomal Dominant Polycystic Kidney trials with a reported enrollment target (14% higher).
The record links to 4 conditions, with Autosomal Dominant Polycystic Kidney appearing as the primary indexed condition, and to 0 interventions.
NCT04111692 reports a single indexed study location in Minnesota.
Frequently Asked Questions
What is clinical trial NCT04111692 about?
NCT04111692 is a clinical study titled "A Prospective Observational Study of Foam Sclerotherapy .". An observational prospective study to determine the impact of foam sclerotherapy of large, dominant kidney/liver cysts on quality of life outcomes and kidney/liver cyst volumes at up to 12 months of follow-up in patients with autosomal dominant polycystic kidney disease (ADPKD) and autosomal dominan...
What is the current status of trial NCT04111692?
This trial is currently recruiting. The enrollment target is 100 participants. The study started on 2017-11-06. Estimated completion is 2027-11.
What conditions does trial NCT04111692 study?
This clinical trial studies the following conditions: Autosomal Dominant Polycystic Kidney, Renal Cyst, Autosomal Dominant Polycystic Liver Disease, Hepatic Cyst.
Who is sponsoring clinical trial NCT04111692?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04111692 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Autosomal Dominant Polycystic Kidney
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Glucagon-Like Peptide-1 Receptor Agonist in ADPKD
RECRUITING · Phase 2
-
Statin Therapy in Patients With Early Stage ADPKD
ACTIVE NOT RECRUITING · Phase 4
-
Renal Oxygen Consumption, Insulin Sensitivity, and Daily Caloric Restriction in ADPKD
ACTIVE NOT RECRUITING · NA
-
Daily Caloric Restriction in ADPKD
ACTIVE NOT RECRUITING · NA
-
A Phase 2 Trial of the Safety and Efficacy of Bardoxolone Methyl in Patients With Rare Chronic Kidney Diseases - PHOENIX
COMPLETED · Phase 2
-
A Clinical Trial of Water Therapy for Autosomal Dominant Polycystic Kidney Disease
COMPLETED · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01048281 · 100 participants
Clinical & Pathological Studies of Upper Gastrointestinal Carcinoma
- NCT01161199 · 100 participants
The Use of Leukapheresis to Support HIV Pathogenesis Studies
- NCT01327690 · 100 participants · Early Phase 1
Mental Health in Veterans and Families After Group Therapies
- NCT01730781 · 100 participants
Imaging Cannabinoid Receptors Using Positron Emission Tomography (PET) Scanning
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI